Efficacy of cefpodoxime in the prophylaxis of recurrent pharyngotonsillitis.
BACKGROUND
Recurrent acute pharyngotonsillitis remains a common illness in children and young adults and can lead to serious complications if not treated. cefpodoxime proxetil is a second-generation oral cephalosporin, which shows potent antibacterial activity against both Gram-positive and Gram-negative bacteria and high stability in the presence of beta-lactamases.


OBJECTIVE
We aimed to evaluate the efficacy of second-generation cephalosporins in the prophylaxis of recurrent pharyngotonsillitis in children.


METHODS
A total of 180 children aged between 4 and 14 years with recurrent pharyngotonsillitis were randomized to receive either cefpodoxime proxetil (100 mg twice a day, 6 days a month for 6 months) or placebo (at the same dosage).


CONCLUSIONS
Our results show that treatment with cefpodoxime proxetil may be effective in reducing symptoms of recurrent pharyngotonsillitis and preventing recurrences without causing side effects or developing bacterial resistance.
Mora
Renzo
R
ENT Department, University of Genoa, Largo R. Benzi 10, Genova 16100, Italy. renzomora@libero.it
Salami
Angelo
A
Mora
Francesco
F
Cordone
Maria Paola
MP
Ottoboni
Stefano
S
Passali
Giulio Cesare
GC
Barbieri
Marco
M
D000293:Adolescent; D019072:Antibiotic Prophylaxis; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use*; D002511:Cephalosporins / Q000494:pharmacology* / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D010612:Pharyngitis / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D055502:Secondary Prevention; D014069:Tonsillitis / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D000097623:Cefpodoxime
D015296:Ceftizoxime; D002511:Cephalosporins; D000097623:Cefpodoxime